We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Elevance Health Shrinks to Grow Stronger: From Part D to Plan B?
Read MoreHide Full Article
Key Takeaways
Elevance will exit standalone Part D and scale back underperforming Medicare Advantage markets.
The insurer will focus on HMO and D-SNP plans, which offer stronger margins.
ELV cut its 2025 EPS outlook to $30, down from the prior $34.15-$34.85, amid rising medical costs.
Elevance Health, Inc. (ELV - Free Report) is reshaping its Medicare strategy by stepping away from certain underperforming Medicare Advantage markets and fully exiting the standalone Part D segment. The move comes as health insurers brace for a turbulent 2026, and it could help Elevance protect profitability while sharpening its competitive edge.
Rather than spread itself thin, Elevance is channeling resources into Medicare Advantage HMO as well as dual-special needs plans (D-SNPs), which typically generates stronger margins and attracts steady enrollment growth. The company’s trailing 12-month return on capital stands at 10.4%, notably above the industry’s 7.4% average, suggesting it has room to navigate headwinds with discipline.
The exit will impact roughly 150,000 of Elevance’s total 2.3 million Medicare Advantage members. With medical costs rising and reimbursement pressures mounting, such retrenchment reflects a broader industry theme: insurers recalibrating to safeguard margins. Indeed, the challenge of underestimated medical costs has forced many to revise their outlooks.
UnitedHealth Group Incorporated (UNH - Free Report) , the market leader, and Molina Healthcare, Inc. (MOH - Free Report) have also trimmed their 2025 forecasts alongside Elevance. ELV now expects 2025 adjusted EPS of about $30, down from its prior $34.15–$34.85 range. UnitedHealth slashed its adjusted net EPS outlook to at least $16, abandoning its previous $26–$26.50 target. UNH is also expected to withdraw from certain Medicare Advantage markets, impacting an estimated 600,000 beneficiaries. Molina Healthcare lowered its 2025 adjusted EPS forecast to at least $19, down from $24.50.
Elevance’s exit from Part D will likely further reshape the landscape. According to KFF, the company ranks as the sixth-largest standalone Part D provider. Its departure will reduce choices for beneficiaries, a continuation of the recent trend. The insurer also faces financial strain from losing a legal battle over its 2025 star ratings. That setback is projected to cost approximately $375 million next year, per reports.
As the Medicare Advantage environment grows more complex, ELV is betting that sharper focus, tighter cost discipline and resilience in core products will put it on firmer footing for the years ahead.
Elevance’s Price Performance, Valuation and Estimates
Shares of ELV have lost 14.6% in the year-to-date period compared with the industry’s decline of 2.9%.
Image Source: Zacks Investment Research
From a valuation standpoint, Elevance trades at a forward price-to-earnings ratio of 10.06, down from the industry average of 14.90. ELV has a Value Score of A at present.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Elevance’s 2025 earnings is pegged at $29.88 per share, implying a 9.6% decline from the year-ago period.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #4 (Sell).
Image: Bigstock
Elevance Health Shrinks to Grow Stronger: From Part D to Plan B?
Key Takeaways
Elevance Health, Inc. (ELV - Free Report) is reshaping its Medicare strategy by stepping away from certain underperforming Medicare Advantage markets and fully exiting the standalone Part D segment. The move comes as health insurers brace for a turbulent 2026, and it could help Elevance protect profitability while sharpening its competitive edge.
Rather than spread itself thin, Elevance is channeling resources into Medicare Advantage HMO as well as dual-special needs plans (D-SNPs), which typically generates stronger margins and attracts steady enrollment growth. The company’s trailing 12-month return on capital stands at 10.4%, notably above the industry’s 7.4% average, suggesting it has room to navigate headwinds with discipline.
The exit will impact roughly 150,000 of Elevance’s total 2.3 million Medicare Advantage members. With medical costs rising and reimbursement pressures mounting, such retrenchment reflects a broader industry theme: insurers recalibrating to safeguard margins. Indeed, the challenge of underestimated medical costs has forced many to revise their outlooks.
UnitedHealth Group Incorporated (UNH - Free Report) , the market leader, and Molina Healthcare, Inc. (MOH - Free Report) have also trimmed their 2025 forecasts alongside Elevance. ELV now expects 2025 adjusted EPS of about $30, down from its prior $34.15–$34.85 range. UnitedHealth slashed its adjusted net EPS outlook to at least $16, abandoning its previous $26–$26.50 target. UNH is also expected to withdraw from certain Medicare Advantage markets, impacting an estimated 600,000 beneficiaries. Molina Healthcare lowered its 2025 adjusted EPS forecast to at least $19, down from $24.50.
Elevance’s exit from Part D will likely further reshape the landscape. According to KFF, the company ranks as the sixth-largest standalone Part D provider. Its departure will reduce choices for beneficiaries, a continuation of the recent trend. The insurer also faces financial strain from losing a legal battle over its 2025 star ratings. That setback is projected to cost approximately $375 million next year, per reports.
As the Medicare Advantage environment grows more complex, ELV is betting that sharper focus, tighter cost discipline and resilience in core products will put it on firmer footing for the years ahead.
Elevance’s Price Performance, Valuation and Estimates
Shares of ELV have lost 14.6% in the year-to-date period compared with the industry’s decline of 2.9%.
From a valuation standpoint, Elevance trades at a forward price-to-earnings ratio of 10.06, down from the industry average of 14.90. ELV has a Value Score of A at present.
The Zacks Consensus Estimate for Elevance’s 2025 earnings is pegged at $29.88 per share, implying a 9.6% decline from the year-ago period.
The stock currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.